Cybersecurity experts conduct hacker test on medical devices

Cybersecurity experts tested the vulnerability of software and medical devices at a group of hospitals, and they found hacking into the healthcare system is a lot easier than expected, reports WUSA9.

In a study conducted by Independent Security Evaluators (ISE), cybersecurity experts tested the hackability of hospital software and medical devices in charge of keeping patients alive. Of the 12 hospitals surveyed "100 percent were found to have critical security vulnerabilities which, if exploited, could result in patient harm or fatality," said Ted Harrington, ISE executive partner. 

Over the course of two years, ISE was able to hack into and control patient monitors and breathing tubes, trigger a false alarm prompting hospital staff to administer unnecessary treatment, and they were able to bypass the online authentication process so that a medical device may be "weaponized" against a targeted patient.  

Harrington’s study gives advice on how to protect against these attacks, including restructuring the hospital for this new generation of technology, sanctioning off specific IT and IS (information security) departments so that hospital and patient safety is always a top concern, and funding digital safety for employees to lower the risk of catching malware.

"...[H]ealthcare is a complex, highly regulated industry, in which it is often difficult to adapt quickly to evolving conditions. For these reasons, we felt compelled to create, publish and give away the blueprint outlined in our research. This will help a healthcare organization of any size plan for and execute the long term process of improving its security posture," said Harrington.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.